Hematopoiesis is the complex process by which mature blood cells of distinct lineages are produced from pluripotent hematopoietic stem cells (HSCs). Defects in this process leads to several hematological malignancies. Ribonuclease Inhibitor (RNH1) is a cytosolic protein and known to inhibit ribonucleases. Recently, we published that RNH1 is a ribosomal associated protein and regulates erythropoiesis by controlling the translation of erythroid specific transcription factor GATA (J Clin Invest. 2018; 28(4):1597-1614). Further studies in our lab identified critical role for RNH1 in adult HSCs function and lineage choice. Loss of RNH1 leads to decrease in HSCs function and increase in myelopoiesis. We have also supportive evidence that RNH1 might play a role in myeloid malignancies such as Myelodysplastic syndrome (MDS) and Acute myeloid leukemia (AML). This proposal aims to understand the detailed molecular mechanism of RNH1 in HSC biology and myeloid malignancies.
The successful applicant will work with state-of-the art techniques in molecular & cell biology, cell culture, protein and molecular biology techniques and the use of mouse transgenic models. The present project is salaried by a grant of the Swiss Cancer research. Applicants with a PhD degree and experience in Hematopoiesis or myeloid malignancies are kindly asked to submit their application.